Navigation Links
960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter
Date:3/18/2008

occur when micro-organisms contaminate the catheter. Catheter related bloodstream infections are estimated to occur at an annual rate of 80,000 to 250,000 cases in the US, resulting in increased mortality, cost, and length of stay.(1-4) The attributable mortality of CRBSI is estimated at 11%.(5) In the U.S., the cost per catheter-related infection can range from $3,700 to $29,000.(6) In addition, the Centers for Disease Control and Prevention (CDC) has raised concerns about the overuse of traditional antibiotics and antiseptics, which can contribute to an increase in bacterial resistance.

About Angiotech's 5-FU CVC

Angiotech has demonstrated that 5-FU, a well-known and approved compound, has utility to prevent catheter-related infections as effectively as traditional antiseptics and antibiotics. In addition, since 5-FU has no clinical application as either a systemic antibiotic or a hospital antiseptic, there is a reduced risk to the hospital or the community at-large of creating a "super-bug" that may be resistant to useful classes of antibiotics and antispectics and may make infection control more complex. The alarming increase in microbial resistance is one of the CDC's top concerns.

The principle behind using 5-FU on a CVC is that the drug acts through multiple pathways to inhibit bacterial growth and metabolic functions of most microorganisms. Adding a very minute amount of 5-FU to the surface of a device makes that surface a very hostile environment for a microorganism, with unchanged tolerability for the patient. Our 5-FU technology can also effectively impair biofilm formation that may lead to colonization and infection. This reduction in colonization by bacteria may have a net effect of reducing biofilm burden on the implanted devices, making them less likely to serve as reservoirs for additional infection.

Note on Forward Looking Statements

Statements contained in this press release that are not based on historical fact,
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Meet ARGUS, The World,s First Contactless Facial ... Analyze emotions and predict actions. Explore a New Generation ... Responsive-RPG: "The Eye: Genesis".      (Photo: ... https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 Imagine being ... - and those of others. Being able to read ...
(Date:6/2/2015)... 2, 2015   Hospira, Inc. (NYSE: ... that its partner, Celltrion – a global biopharmaceutical company – ... Surveillance Agency in Brazil – ... for use in Brazil . The ... and sells biosimilar infliximab in 26 European countries and ...
(Date:6/2/2015)... 2, 2015   BioClinica ® , Inc., ... announced that David Peters , an accomplished senior ... President and Chief Financial Officer (CFO) and will be ... brings more than 25 years of financial and accounting ... extensive and deep knowledge in all areas of finance, ...
(Date:6/2/2015)... June 2, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that Dr. Pamela Pavco ... at the 23 rd World Congress ... will include in-depth presentations by world-class clinicians ...
Breaking Biology Technology:ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5BioClinica Names David Peters New Chief Financial Officer 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4
... Pain Management business, NATICK, Mass., Jan. 4 ... announced that it has completed the sale of,the ... pump,development program to former principals and shareholders of ... The sale,coincides with the closing of the amended ...
... YORK, Jan. 4 QED International,Associates, Inc., administrator ... indexes for the HealthShares(TM) Exchange-Traded Funds,today announced that ... January,7, 2008, Maxygen, Inc. (Nasdaq: MAXY ) ... in the HealthShares(TM) Autoimmune-Inflammation Index.,Alpharma, Inc. (NYSE: ...
... ARLINGTON, Va., Jan. 4 Faced with ... suppliers are turning their attention to,opportunities in ... navigate these unfamiliar waters, leading research and,advisory ... report,examining the marketing and media preferences of ...
Cached Biology Technology:Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program 2Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program 3QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes 2Study Examines Media Preferences of Life Scientists in Applied Markets 2Study Examines Media Preferences of Life Scientists in Applied Markets 3
(Date:6/1/2015)... -- According to a new market ... (Government, Military & Defense, Healthcare, Banking & Finance, ... (Face Recognition, Fingerprint Recognition, Iris Recognition, Palm Recognition, ... Function (Contact and Non-Contact) & Geography ( ... , APAC, Row) - Global Forecast to 2020", ...
(Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
(Date:5/22/2015)... CT , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... June 1st, it will be ending its promotional pricing and ... . Laurence Savin , Head of Marketing ... exclusive promotional pricing until the end of May. To get ... wocketwallet.com/invite and when we open the store on June 1, ...
Breaking Biology News(10 mins):Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... economy of the cell, little bubbles called vesicles serve ... port - the cell membrane. Some of these vesicles, ... protein factory. Scientists have long believed that other, ... and proteins through an independent process. By using a ...
... A revolutionary new protein stabilisation technique has been ... Sciences Research Council (BBSRC) which could lead to 30 ... for drug development - opening up exciting possibilities in ... a vital first step in developing new drugs, but ...
... and China have gathered in Barcelona this week to report ... data from ESA and Chinese Earth observation satellites. Dragon ... of Science and Technology (MOST) of China encourages scientists ... environmental phenomena in China. ,The symposium, held in Barcelona,s World ...
Cached Biology News:Cells use import machinery to export their goods as well 2Cells use import machinery to export their goods as well 3New nanoparticles could revolutionize therapeutic drug discovery 2Europe and China watching Earth together 2
... Engine instrument is the cycler that ... thermal uniformity and swappable blocks ensure ... This rugged machine is more ... platform for new features and upgrades ...
... The Easy Cap tool provides ... seat domed double-locking caps in tubes ... has a wide end that firmly ... prevent accidental crushing when opening or ...
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... (MSTA) slides were designed to study protein expression ... species. Tissue slices from three different species ... then be treated as a single histological slide ... hybridization. This format allows a rapid ...
Biology Products: